ANI Pharmaceuticals Overview
Valuation check: ANIP's P/E ratio is 16.2, below the Healthcare sector average of 26.36.
Get informed when a big investor buys or sells
+ Follow16.20
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for ANIP is 16.2. That is below the Healthcare sector average of 26.36. Investors often review this figure alongside ANI Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, ANIP currently prints 16.2 for P/E ratio, while the sector average sits near 26.36. That is roughly 38.5% below the sector mean. Large gaps often invite a closer look at ANI Pharmaceuticals's growth, margins, and balance sheet.
A P/E ratio of 16.2 for ANI Pharmaceuticals is not 'good' or 'bad' on its own. Compare it with the peer average (26.36) and with ANIP's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting ANIP's P/E ratio (16.2), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack ANI Pharmaceuticals's P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
